ALZHEIMER'S ASSOCIATION WELCOMES FDA ACTION APPROVING LEQEMBI WEEKLY SUBCUTANEOUS MAINTENANCE DOSING

ALZHEIMER'S ASSOCIATION WELCOMES FDA ACTION APPROVING LEQEMBI WEEKLY SUBCUTANEOUS MAINTENANCE DOSING

CHICAGO, Aug. 29, 2025 /PRNewswire/ -- The Alzheimer's Association welcomes today's U.S. Food and Drug Administration (FDA) action to approve weekly subcutaneous maintenance dosing of Leqembi® (lecanemab, Eisai/Biogen) for early Alzheimer's disease. With this approval, Leqembi IQLIK is the first…

Biogen wins approval of at-home version of Alzheimer's drug Leqembi

FDA approves at-home injection for Biogen and Eisai's Alzheimer's drug Leqembi. Read more here.

FDA approves Eisai and Biogen’s Leqembi Iqlik BLA for early Alzheimer’s

This new dosing option enables patients with mild cognitive impairment or mild dementia to receive treatment at home, following an initial intravenous (IV) administration. Leqembi Iqlik, administered through The post FDA approves Eisai and Biogen’s Leqembi Iqlik BLA for early Alzheimer’s appeared first on Pharmaceutical Business review.

FDA Approves Lecanemab Autoinjector, Marking First At-Home Treatment for Alzheimer Disease

The autoinjector, branded as Leqembi Iqlik, contains a 360 mg/1.8 mL dose administered over 15 seconds. It is expected to enhance Alzheimer treatment accessibility and offer cost savings for patients.

First-Ever At-Home Injection Treatment for Alzheimer's: FDA Approves LEQEMBI IQLIK's 15-Second Administration

Eisai/Biogen's LEQEMBI IQLIK autoinjector enables weekly at-home treatment after 18 months of IV therapy. Shows comparable benefits to IV dosing with 99% fewer systemic reactions. Launches Oct 6, 2025.

FDA Approves LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease

LEQEMBI IQLIK is the first and only anti-amyloid treatment to offer an at-home injection to help patients and care partners continue to treat this progressive, relentless disease after initial treatment of 18 months